Details of the Drug Combination

General Information of Drug Combination (ID: DCAZGHB)

Drug Combination Name
Glycopyrrolate MCD-386
Indication
Disease Entry Status REF
Alzheimer disease Investigative [1]
Component Drugs Glycopyrrolate   DM2M3ZA MCD-386   DMFIS4D
Small molecular drug N.A.
2D MOL 2D MOL
3D Structure is Not Available
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Glycopyrrolate
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [2]
Chronic obstructive pulmonary disease CA22 Approved [3]
Glycopyrrolate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Glycopyrrolate Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Indication(s) of MCD-386
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [4]
MCD-386 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Agonist [7]
------------------------------------------------------------------------------------

References

1 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7459).
3 Clinical pipeline report, company report or official report of Novartis.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009639)
5 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
6 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
7 The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5.